ArticleEULAR rheumatology open2026
LLM-supported self-diagnosis and self-treatment of familial Mediterranean fever: a case report.
Article in EULAR rheumatology open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Large language models (LLMs) are increasingly being used by patients to seek explanations for persistent or unexplained symptoms. However, their impact on real-world diagnostic pathways and patient behavior remains poorly understood. We report the case of a 34-year-old male of Egyptian origin with recurrent episodes of fever, severe migratory abdominal pain, arthralgia, myalgia, and intermittent erythematous skin lesions since early childhood. Despite almost 3 decades of extensive investigations, no unifying diagnosis had been established. During an iterative dialogue with the LLM DeepSeek in June 2025, the differential diagnosis was progressively refined toward familial Mediterranean fever (FMF). Although the model repeatedly recommended specialist assessment, it also provided specific information regarding genetic testing and colchicine treatment. The patient subsequently arranged genetic testing independently and obtained colchicine in Egypt, initiating treatment without prior specialist assessment at 0.5 mg twice daily. His inflammatory attacks ceased completely. However, liver enzymes increased, prompting temporary treatment discontinuation and dose reduction. FMF was thereafter confirmed by specialist assessment based on the characteristic clinical phenotype, family history, genotype, and response to colchicine. This case illustrates how patient-facing LLMs may facilitate recognition of rare autoinflammatory diseases. However, confident diagnostic language combined with actionable treatment advice may also encourage unsupervised testing and self-medication, underscoring the need for clear safety boundaries and specialist confirmation.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.